BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang Y, Gauthier A, Keeping S, Carroll S. A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res 2014;14:901-11. [PMID: 25186657 DOI: 10.1586/14737167.2014.953932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang Y, Gervais F, Gauthier A, Baptiste C, Martinon P, Bresse X. A comparative public health and budget impact analysis of pneumococcal vaccines: The French case. Hum Vaccin Immunother 2015;11:2188-97. [PMID: 26267239 DOI: 10.1080/21645515.2015.1011957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Garattini L, Padula A, Da Costa MR. Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering? Pharmacoeconomics 2016;34:221-4. [PMID: 26518294 DOI: 10.1007/s40273-015-0341-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Steens A, Vestrheim DF, de Blasio BF. Pneumococcal vaccination in older adults in the era of childhood vaccination: Public health insights from a Norwegian statistical prediction study. Epidemics 2015;11:24-31. [PMID: 25979279 DOI: 10.1016/j.epidem.2015.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
4 Rodríguez González-Moro JM, Menéndez R, Campins M, Lwoff N, Oyagüez I, Echave M, Rejas J, Antoñanzas F. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. Clin Drug Investig 2016;36:41-53. [PMID: 26547199 DOI: 10.1007/s40261-015-0345-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
5 Cafiero-Fonseca ET, Stawasz A, Johnson ST, Sato R, Bloom DE. The full benefits of adult pneumococcal vaccination: A systematic review. PLoS One 2017;12:e0186903. [PMID: 29088258 DOI: 10.1371/journal.pone.0186903] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
6 Porchia BR, Bonanni P, Bechini A, Bonaccorsi G, Boccalini S. Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Rev Vaccines 2017;16:93-107. [PMID: 27680425 DOI: 10.1080/14760584.2017.1242419] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yang TU, Kim E, Park YJ, Kim D, Kwon YH, Shin JK, Park O. Successful introduction of an underutilized elderly pneumococcal vaccine in a national immunization program by integrating the pre-existing public health infrastructure. Vaccine 2016;34:1623-9. [PMID: 26850759 DOI: 10.1016/j.vaccine.2016.01.043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
8 Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, Kim WJ, Kim MJ, Lee HY, Song JY. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One 2017;12:e0177342. [PMID: 28498857 DOI: 10.1371/journal.pone.0177342] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]